Corporate Report

The report integrates KAKEN's financial, environmental, and social reporting into one corporate report prepared with reference to the IIRC disclosure framework. For FY2017, the company reported consolidated net sales of ¥98,430 million and continued to focus on its pharmaceuticals-led business, including Clenafin and its R&D pipeline. Environmental highlights for the Shizuoka site and Kyoto Drug Research Center included 26,227 t-CO2 emissions, 2,603 tons of waste discharged, and a 99.2% waste recycling rate. The report also records 1,389 consolidated employees as of March 31, 2018.